SB225002与顺铂联合应用对口腔鳞癌细胞作用的体外研究

doi:10.13701/j.cnki.kqyxyj.2016.02.007

口腔医学研究 ›› 2016, Vol. 32 ›› Issue (2): 134-138.DOI: 10.13701/j.cnki.kqyxyj.2016.02.007

SB225002与顺铂联合应用对口腔鳞癌细胞作用的体外研究

王仙林¹ 刘建伟² 钱永^2*

1. 江西省信丰县骨伤科医院口腔科江西赣州 341600;
2. 南昌大学第一附属医院口腔颌面外科江西南昌 330006

收稿日期:2015-08-10 出版日期:2016-02-28 发布日期:2016-03-10
通讯作者: 钱永,E-mail:yfykqkqy@163.com
作者简介:王仙林(1978~),男,江西人,学士,主治医师,主要从事口腔科的临床治疗工作。
基金资助:
国家自然科学基金项目(编号:81060087、81460410)
江西省自然科学基金项目(编号:20151BAB205029)

Effects of Combined Chemotherapy of SB225002 and Cisplatin on OSCC Cells In Vitro

WANG Xian-ling¹, LIU Jian-wei², QIAN Yong².

1. Department of Stomatology, Orthopaedic Hospital, Xinfeng 341600, China;
2. Department of Oral and Maxillofacial Surgery, First Affiliated Hospital, Nanchang University, Nanchang 330006, China

Received:2015-08-10 Online:2016-02-28 Published:2016-03-10

摘要/Abstract

摘要： 目的:观察SB225002与顺铂联合应用对口腔鳞癌细胞的增殖、凋亡及细胞周期的影响,并探讨其机制。方法:分别采用MTT试验及流式细胞术检测SB225002与顺铂单独或联合应用对体外培养的口腔鳞癌细胞的增殖、凋亡及细胞周期的影响,并进行相关分析。结果:在单独应用时,SB225002可一定浓度范围内显著抑制口腔鳞癌细胞的增殖,促进其凋亡,并诱导细胞发生G₂/M期阻滞,作用随浓度升高而增强。SB225002与顺铂联合应用时,联合组对口腔鳞癌细胞的抑制效果明显强于单独用药组,P<0.05。在一定浓度范围内,SB225002可显著促进口腔鳞癌细胞的凋亡,并诱导细胞发生G₂/M期阻滞,其作用随浓度的升高而增强;而SB225002与顺铂联合应用时,联合组的促调亡及诱导细胞G₂/M期阻滞作用均显著强于单独用药组,P<0.05。结论:SB225002单独或与顺铂联合应用时,均可显著抑制口腔鳞癌细胞的增殖,促进其凋亡,并诱导细胞发生G₂/M期阻滞,两者之间存在协同作用。

关键词: SB225002, 顺铂, 口腔鳞癌, 协同作用

Abstract: Objective: To investigate the effects of SB225002 and cisplatin on oral squamous cell carcinoma (OSCC) cells, and meanwhile explore the possible mechanism. Methods: The OSCC cell proliferation, apoptosis and cell cycle were detected by MTT assay and flow cytometry after treated with SB225002 and cisplatin alone or in combination, and then correlated analysis was performed. Results: SB225002 could significantly inhibit the proliferation, promote apoptosis and induce G2/M arrest of OSCC cells in a concentration-dependent manner. Moreover, combined chemotherapy of SB225002 and cisplatin showed stronger effects, and the differences were statistically significant (P<0.05). Conclusion: There is synergistic effect between SB225002 and cisplatin on the anti-tumor activity in OSCC cells.

中图分类号:

R739.8

王仙林,刘建伟,钱永. SB225002与顺铂联合应用对口腔鳞癌细胞作用的体外研究[J]. 口腔医学研究, 2016, 32(2): 134-138.

WANG Xian-ling, LIU Jian-wei, QIAN Yong.. Effects of Combined Chemotherapy of SB225002 and Cisplatin on OSCC Cells In Vitro[J]. Journal of Oral Science Research, 2016, 32(2): 134-138.

参考文献

[1] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics[J]. 2002. CA Cancer J lin, 2005, 55∶74-108
[2] Rodriguez CP, Adelstein DJ. Survival trends in head and neck cancer: opportunities for improving outcomes[J]. Oncologist, 2010, 15∶921-3
[3] Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution[J]. Genome Biol, 2006, 7(12)∶243
[4] Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity[J]. J Immunol, 2000, 165(9)∶5269-77
[5] White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibitsinterleukin-8-induced neutrophil migration[J]. J Biol Chem, 1998, 273∶10095-98
[6] Sueoka H, Hirano T, Uda Y, et al. Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma[J]. Surgery, 2014, 155(4)∶640-9
[7] Goda AE, Koyama M, Sowa Y, et al. Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor[J]. Biochem Pharmacol, 2013, 85(12)∶1741-52
[8] Saintigny P, Massarelli E, Lin S, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma[J]. Cancer Res, 2013, 73(2)∶571-82
[9] Machiels JP, Lambrecht M, Hanin FX, et al. Advances in the management of squamous cell carcinoma of the head and neck[J]. F1000Prime Rep, 2014, 6∶44
[10] Wolff KD, Follmann M, Nast A. The diagnosis and treatment of oral cavity cancer[J]. Dtsch Arztebl Int, 2012, 109(48)∶829-35
[11] Bredell M, Rordorf T, Studer G. Treatmentconceptsof oral cancer[J].SADJ, 2012, 67(10)∶574-6
[12] Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action[J]. Eur J Pharmacol, 2014, 740∶364-78
[13] Andreadis C, Vahtsevanos K, Sidiras T, et al. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer[J]. Oral Oncol, 2003, 39(4)∶380-5
[14] Ren W, Wang X, Gao L, et al. MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4[J]. Mol Cell Biochem, 2014, 390(1-2)∶253-62
[15] Shapiro LQ, Sherman EJ, Riaz N, et al. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC)[J]. Oral Oncol, 2014, 50(10)∶947-55
[16] Huang CE, Yu CC, Hu FW, et al. Enhanced chemosensitivity by targeting Nanog in head and neck squamous cell carcinomas[J]. Int J Mol Sci, 2014, 15(9)∶14935-48
[17] Saintigny P, Massarelli E, Lin S, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma[J]. Cancer Res, 2013, 73(2)∶571-82
[18] Lee YS, Choi I, Ning Y, et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis[J]. Br J Cancer, 2012, 106(11)∶1833-41
[19] White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration[J]. J Biol Chem, 1998, 273(17)∶10095-8
[20] Catusse J, Liotard A, Loillier B, et al. Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogene alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2[J]. Biochem Pharmacol, 2003, 65(5):813-21
[21] Du M, Qiu Q, Gruslin A, et al. SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro[J]. PLoS One, 2013, 8(1)∶e54572
[22] Qian Y, Wang Y, Li DS, et al. The chemokine receptor-CXCR2 plays a critical role in the invasion and metastases of oral squamous cellcarcinoma in vitro and in vivo[J]. J Oral Pathol Med, 2014, 43(9)∶658-66
[23] 王雷,蔡研,孙宏晨.重组人乳铁蛋白对口腔癌细胞周期及周期因子表达影响的实验研究.口腔医学研究,2010,26(1)∶19-21
[24] Chang Q, Ornatsky OI, Koch CJ, et al. Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry[J]. Int J Cancer,2014,[Epub ahead of print]
[25] Liu FY, Wu YH, Zhou SJ, et al. Minocycline and cisplatin exert synergistic growth suppression on hepatocellular carcinoma by inducing S phase arrest and apoptosis[J]. Oncol Rep, 2014, 32(2)∶835-44

SB225002与顺铂联合应用对口腔鳞癌细胞作用的体外研究

Effects of Combined Chemotherapy of SB225002 and Cisplatin on OSCC Cells In Vitro

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王蕊,李立恒,胥爱文,安峰. 慢病毒介导的Med19表达下调提高舌鳞癌细胞顺铂敏感性[J]. 口腔医学研究, 2019, 35(6): 559-562.
[2]	王玉梅,刘炜炜,陈力. 口腔鳞癌患者血清膜联蛋白A2表达及其与放疗敏感性的关系[J]. 口腔医学研究, 2019, 35(2): 133-136.
[3]	汪晓龙,曹顺顺,张鹏,舒传继,夏林. 人源性长寿保障基因2在口腔鳞癌组织中表达及对细胞增殖和侵袭能力的影响[J]. 口腔医学研究, 2019, 35(2): 142-146.
[4]	章思莹，潘淑婷，帅芳源，邱嘉旋. PI3K/AKT/mTOR/p70S6K通路在人舌鳞癌细胞耐药中的作用[J]. 口腔医学研究, 2017, 33(9): 938-942.
[5]	郑政，何盈洋，谢狄亚，陈艳，王泽正，郝峰瑶，王志勇. Rab38在口腔鳞癌中的表达及临床意义[J]. 口腔医学研究, 2017, 33(9): 946-949.
[6]	杨洋, 郑军, 徐江, 顾永清, 黄瑾, 王丹妮, 朱茂祥, 曾妍. Naa10基因RNA干扰慢病毒载体的构建及其对口腔鳞癌细胞生长的影响[J]. 口腔医学研究, 2017, 33(7): 707-711.
[7]	贾宝超, 关键, 戴辛鹏, 杨键, 王建杰, 刘东璞. Nrf2、HO-1在口腔鳞癌组织中的表达及其临床意义[J]. 口腔医学研究, 2017, 33(2): 207-210.
[8]	曾光,卫克文. MAP4K3-mTOR信号在甘草查而酮A诱导的鳞癌细胞自噬与凋亡中的作用研究[J]. 口腔医学研究, 2017, 33(12): 1241-1245.
[9]	邬利波,潘淑婷,邱嘉旋. 口腔鳞癌新辅助化疗前后多药耐药相关蛋白的表达及临床疗效分析[J]. 口腔医学研究, 2017, 33(12): 1298-1301.
[10]	王媛，翦新春，刘德裕. 应用QPCR验证口腔黏膜下纤维性变癌变分子标记物的研究[J]. 口腔医学研究, 2017, 33(10): 1027-1030.
[11]	蒋丽娟,郑阳,泥艳红,韩伟,黄晓峰,胡勤刚,王志勇. Avastin联合抗原致敏的DC-CTL细胞体外抑制口腔鳞癌细胞生长的实验研究[J]. 口腔医学研究, 2016, 32(8): 848-852.
[12]	张军,代晓华,邹慧儒,连小丽,李燕妮. EMP1基因对口腔鳞癌细胞增殖、迁移和侵袭影响的体外研究[J]. 口腔医学研究, 2016, 32(12): 1240-1243.
[13]	静广平,吕克文,张晗,吕行. 野黄芩素协同ABT-737抗头颈鳞癌作用的研究[J]. 口腔医学研究, 2016, 32(11): 1188-1192.
[14]	帕拉提·吐尔逊,热孜亚·艾尼,木合塔尔·霍加. P53,Ki-67蛋白在口腔鳞癌中的表达意义及与预后的关系[J]. 口腔医学研究, 2016, 32(1): 87-90.
[15]	殷豪,邓小玲,李国阳,石松林,李祺福,许铭炎. EGFR参与溶血磷脂酸诱导口腔鳞癌细胞整合素β6的表达[J]. 口腔医学研究, 2015, 31(8): 767-.